Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Blinatumomab for Injection
DRUG
2 trials
Sponsors
Seoul National University Hospital
, Institute of Hematology & Blood Diseases Hospital, China
Conditions
Minimal Residual Disease
Pediatric ALL, B Cell
Precursor B-cell Acute Lymphoblastic Leukemia
Phase 1
Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD)
NCT04604691
Seoul National University Hospital
Minimal Residual Disease, Pediatric ALL, B Cell
Start: 2022-02-18
End: 2024-12-31
Target: 20
Updated: 2022-03-08
Phase 3
A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALL
Not yet recruiting
NCT07723911
Institute of Hematology & Blood Diseases Hospital, China
Precursor B-cell Acute Lymphoblastic Leukemia
Start: 2026-08-09
End: 2028-10-10
Target: 212
Updated: 2026-07-23